All In Biotech

Drug Trial Radar · NCT07395024

A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults

A Phase 1 Crossover Design Study to Assess the Effect of CYP3A Moderate and Strong Inhibitors (Fluconazole and Itraconazole) and Strong Inducer (Carbamazepine) on the Single-dose Pharmacokinetics of ASP3082 in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

54

Actual

Start

Feb 3, 2026

Primary completion

May 2, 2027

Study completion May 2, 2027

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Feb 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some people with solid tumors have a faulty KRAS gene. One such change in the KRAS gene is called a G12D mutation. Researchers are looking for ways to stop the actions of abnormal proteins made from the KRAS G12D mutation. ASP3082 is thought to replace some of the abnormal proteins made from the faulty KRAS gene. If other medicines are given at the same time as ASP3082, they may affect how the body processes ASP3082. In this study, fluconazole, itraconazole and carbamazepine are given with ASP3082 in healthy adults. The main aims are to check if fluconazole, itraconazole and carbamazepine affect how the body processes ASP3082. These medicines may affect how the body processes ASP3082 when they are taken at the same time. This study will have 3 groups of adults. One group will be given fluconazole and ASP3082, the second group will be given carbamazepine and ASP3082, and the third group will be given itraconazole and ASP3082. ASP3082 will be given to people slowly through a tube into the vein (infusion). Fluconazole and carbamazepine will be given as a tablet and itraconazole will be given as a liquid by mouth. People will be given study treatments for about 1 month. They will then return to the clinic about 1 week after they finish study treatment for a final safety check.

Conditions

  • Healthy Volunteer

Interventions

  • SetidegrasibDrug

    Intravenous (IV) infusion

  • FluconazoleDrug

    Oral

  • CarbamazepineDrug

    Oral

  • ItraconazoleDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) of ASP3082 in plasma: Maximum Concentration (Cmax) in ASP3082Time frame: Up to 29 days
  2. PK of ASP3082 in plasma: area under the concentration-time curve from time zero to the time of the last measurable concentration (AUClast) in ASP3082Time frame: Up to 29 days
  3. PK of ASP3082 in plasma: area under the concentration-time curve extrapolated to infinity (AUCinf) in ASP3082Time frame: Up to 29 days
  4. PK of ASP3082 in plasma: Cmax in ASP3082+ Fluconazole (FLZ)Time frame: Up to 29 days
  5. PK of ASP3082 in plasma: AUClast in ASP3082+FLZTime frame: Up to 29 days
  6. PK of ASP3082 in plasma: AUCinf in ASP3082+FLZTime frame: Up to 29 days
  7. Ratio of Cmax of ASP3082 and ASP3082+FLZTime frame: Up to 29 days
  8. Ratio of AUClast of ASP3082 and ASP3082+FLZTime frame: Up to 29 days
  9. Ratio of AUCinf of ASP3082 and ASP3082+FLZTime frame: Up to 29 days
  10. PK of ASP3082 in plasma: Cmax in ASP3082+ Itraconazole (ITZ)Time frame: Up to 29 days
  11. PK of ASP3082 in plasma: AUClast in ASP3082+ITZTime frame: Up to 29 days
  12. PK of ASP3082 in plasma: AUCinf in ASP3082+ITZTime frame: Up to 29 days
  13. Ratio of Cmax of ASP3082 and ASP3082+ITZTime frame: Up to 29 days
  14. Ratio of AUClast for ASP3082 and ASP3082+ITZTime frame: Up to 29 days
  15. Ratio of AUCinf for ASP3082 and ASP3082+ITZTime frame: Up to 29 days
  16. PK of ASP3082 in plasma: Cmax in ASP3082+ Carbamazepine (CAR)Time frame: Up to 29 days
  17. PK of ASP3082 in plasma: AUClast in ASP3082+CARTime frame: Up to 29 days
  18. PK of ASP3082 in plasma: AUCinf in ASP3082+CARTime frame: Up to 29 days
  19. Ratio of Cmax of ASP3082 and ASP3082+CARTime frame: Up to 29 days
  20. Ratio of AUClast for ASP3082 and ASP3082+CARTime frame: Up to 29 days
  21. Ratio of AUCinf for ASP3082 and ASP3082+CARTime frame: Up to 29 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.